Background/Aims: To evaluate the incidence rate of relapse in patients with inflammatory bowel disease (IBD) undergoing chondroitin sulphate (CS) treatment and its effect on the concentrations of several pro-inflammatory proteins. Methods: Prospective, observational, 12-month follow-up study in patients with IBD in remission, starting CS (Condrosan®, Bioiberica S.A.) treatment for osteoarthritis (OA). Crohn's Disease Activity Index and modified Truelove-Witts severity index were calculated for Crohn's disease and ulcerative colitis (UC) respectively. Levels of vascular endothelial growth factor (VEGFA), -C, fibroblast growth factor 2, hepatocyte growth factor, angiopoietin (Ang)-1, Ang-2, transforming growth factor beta, tumour necrosis factor alpha, interleukin (IL)-1β, IL-6, IL-12, IL-17, IL-23, intracellular adhesion molecule-1, vascular adhesion molecule-1, matrix metalloproteinase-3 and PGE2 were quantified by ELISA. OA joint pain was evaluated using a visual analogue scale. Results: A total of 37 patients (19 UC and 18 Crohn's disease) were included. The mean values for OA joint pain decreased after 12 months from 5.9 ± 2.8 to 3.0 ± 2.3 (p < 0.05). Only 1 patient (with UC) flared during follow-up. The incidence rate of relapse was 3.4% per patient-year of follow-up. Mean serum VEGFA levels increased between baseline (492 pg/ml) and 12-month treatment (799 pg/ml; p < 0.05). Conclusion: The incidence of IBD relapse in patients under CS treatment was lower than that generally reported. This treatment might modulate VEGFA. CS decreases OA-related pain in patients with IBD.

Keywords:
Ulcerative colitis, Inflammatory bowel disease, Osteoarthritis, Chondroitin sulphate, Interleukins, Crohn’s disease, Angiogenesis
1.
Hardingham TE, Ewins RJ, Muir H: Cartilage proteoglycans. Structure and heterogeneity of the protein core and the effects of specific protein modifications on the binding to hyaluronate. Biochem J 1976;157:127-143.
2.
Cho SY, Sim JS, Jeong CS, Chang SY, Choi DW, Toida T, Kim YS: Effects of low molecular weight chondroitin sulfate on type ii collagen-induced arthritis in DBA/1J mice. Biol Pharm Bull 2004;27:47-51.
3.
Tahiri K, Korwin-Zmijowska C, Richette P, Héraud F, Chevalier X, Savouret JF, Corvol MT: Natural chondroitin sulphates increase aggregation of proteoglycan complexes and decrease ADAMTS-5 expression in interleukin 1 beta-treated chondrocytes. Ann Rheum Dis 2008;67:696-702.
4.
David-Raoudi M, Deschrevel B, Leclercq S, Galéra P, Boumediene K, Pujol JP: Chondroitin sulfate increases hyaluronan production by human synoviocytes through differential regulation of hyaluronan synthases: role of p38 and Akt. Arthritis Rheum 2009;60:760-770.
5.
Imada K, Oka H, Kawasaki D, Miura N, Sato T, Ito A: Anti-arthritic action mechanisms of natural chondroitin sulfate in human articular chondrocytes and synovial fibroblasts. Biol Pharm Bull 2010;33:410-414.
6.
du Souich P: Absorption, distribution and mechanism of action of sysadoas. Pharmacol Ther 2014;142:362-374.
7.
Hochberg M, Chevalier X, Henrotin Y, Hunter DJ, Uebelhart D: Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence? Curr Med Res Opin 2013;29:259-267.
8.
Vallières M, du Souich P: Modulation of inflammation by chondroitin sulfate. Osteoarthritis Cartilage 2010;18(suppl 1):S1-S6.
9.
Herrero-Beaumont G, Marcos ME, Sánchez-Pernaute O, Granados R, Ortega L, Montell E, Vergés J, Egido J, Largo R: Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br J Pharmacol 2008;154:843-851.
10.
Cañas N, Valero T, Villarroya M, Montell E, Vergés J, García AG, López MG: Chondroitin sulfate protects SH-SY5Y cells from oxidative stress by inducing heme oxygenase-1 via phosphatidylinositol 3-kinase/Akt. J Pharmacol Exp Ther 2007;323:946-953.
11.
Martín-de-Saavedra MD, del Barrio L, Cañas N, Egea J, Lorrio S, Montell E, Vergés J, García AG, López MG: Chondroitin sulfate reduces cell death of rat hippocampal slices subjected to oxygen and glucose deprivation by inhibiting p38, NFκB and iNOS. Neurochem Int 2011;58:676-683.
12.
Rolls A, Cahalon L, Bakalash S, Avidan H, Lider O, Schwartz M: A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration. FASEB J 2006;20:547-549.
13.
Morrison LM, Branwood AW, Ershoff BH, Murata K, Quilligan JJ Jr, Schjeide OA, Patek P, Bernick S, Freeman L, Dunn OJ, Rucker P: The prevention of coronary arteriosclerotic heart disease with chondroitin sulfate A: preliminary report. Exp Med Surg 1969;27:278-289.
14.
Andreas K, Lübke C, Häupl T, Dehne T, Morawietz L, Ringe J, Kaps C, Sittinger M: Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther 2008;10:R9.
15.
Möller I, Pérez M, Monfort J, Benito P, Cuevas J, Perna C, Doménech G, Herrero M, Montell E, Vergés J: Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage 2010;18(suppl 1):S32-S40.
16.
Andrés RM, Payá M, Montesinos MC, Ubeda A, Navalón P, Herrero M, Vergés J, Terencio MC: Potential antipsoriatic effect of chondroitin sulfate through inhibition of NF-κB and STAT3 in human keratinocytes. Pharmacol Res 2013;70:20-26.
17.
Schreiber S, Nikolaus S, Hampe J, Hämling J, Koop I, Groessner B, Lochs H, Raedler A: Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999;353:459-461.
18.
Chaparro M, Guerra I, Muñoz-Linares P, Gisbert JP: Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:971-986.
19.
Shintani Y, Takashima S, Asano Y, Kato H, Liao Y, Yamazaki S, Tsukamoto O, Seguchi O, Yamamoto H, Fukushima T, Sugahara K, Kitakaze M, Hori M: Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. EMBO J 2006;25:3045-3055.
20.
Goretzki L, Burg MA, Grako KA, Stallcup WB: High-affinity binding of basic fibroblast growth factor and platelet-derived growth factor-AA to the core protein of the NG2 proteoglycan. J Biol Chem 1999;274:16831-16837.
21.
Zhang Q, Lu Y, Proulx ST, Guo R, Yao Z, Schwarz EM, Boyce BF, Xing L: Increased lymphangiogenesis in joints of mice with inflammatory arthritis. Arthritis Res Ther 2007;9:R118.
22.
Hashiramoto A, Sakai C, Yoshida K, Tsumiyama K, Miura Y, Shiozawa K, Nose M, Komai K, Shiozawa S: Angiopoietin 1 directly induces destruction of the rheumatoid joint by cooperative, but independent, signaling via ERK/MAPK and phosphatidylinositol 3-kinase/Akt. Arthritis Rheum 2007;56:2170-2179.
23.
Lennard-Jones JE: Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6; discussion 16-19.
24.
Satsangi J, Silverberg MS, Vermeire S, Colombel JF: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-753.
25.
Best WR, Becktel JM, Singleton JW: Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979;77:843-846.
26.
Truelove SC, Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-1048.
27.
Salcedo X, Medina J, Sanz-Cameno P, García-Buey L, Martín-Vilchez S, Moreno-Otero R: Review article: angiogenesis soluble factors as liver disease markers. Aliment Pharmacol Ther 2005;22:23-30.
28.
Pousa ID, Maté J, Salcedo-Mora X, Abreu MT, Moreno-Otero R, Gisbert JP: Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. Inflamm Bowel Dis 2008;14:61-67.
29.
Algaba A, Linares PM, Fernández-Contreras ME, Ordoñez A, Trápaga J, Guerra I, Chaparro M, de la Poza G, Gisbert JP, Bermejo F: Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease. J Crohns Colitis 2013;7:e569-e579.
30.
Gisbert JP, Bermejo F, Pérez-Calle JL, Taxonera C, Vera I, McNicholl AG, Algaba A, López P, López-Palacios N, Calvo M, González-Lama Y, Carneros JA, Velasco M, Maté J: Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-1198.
31.
Iovu M, Dumais G, du Souich P: Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 2008;16(suppl 3):S14-S18.
32.
Hori Y, Hoshino J, Yamazaki C, Sekiguchi T, Miyauchi S, Horie K: Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats. Jpn J Pharmacol 2001;85:155-160.
33.
Ota S, Yoshihara S, Ishido K, Tanaka M, Takagaki K, Sasaki M: Effects of proteoglycan on dextran sulfate sodium-induced experimental colitis in rats. Dig Dis Sci 2008;53:3176-3183.
34.
Veritti D, Perissin L, Zorzet S, Lanzetta P: The effect of triamcinolone acetonide, sodium hyaluronate, and chondroitin sulfate on human endothelial cells: an in vitro study. Eur J Ophthalmol 2011;21(suppl 6):S75-S79.
35.
Edwards FC, Truelove SC: The course and prognosis of ulcerative colitis. Gut 1963;4:299-315.
36.
An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine study group. Ann Intern Med 1996;124:204-211.
37.
Mahmud N, Kamm MA, Dupas JL, Jewell DP, O'Morain CA, Weir DG, Kelleher D: Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut 2001;49:552-556.
38.
Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, Schulz T, Stray N, Fausa O: Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol 1997;32:1005-1012.
39.
Gisbert JP, Gomollón F, Maté J, Pajares JM: Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 2002;47:471-488.
40.
Garcia-Planella E, Manyosa M, Chaparro M, Barreiro-de-Acosta M, Beltrán B, Ricart E, García-Sánchez V, Esteve M, Piqueras M, Bermejo F, López-Sanromán A, Taxonera C, Llaó J, Gisbert JP, Cabré E, Domènech E: DOP051 usefulness of a faecal calprotectin rapid semiquantitative test in predicting relapse in patients with ulcerative colitis in remission. J Crohns Colitis 2014;8:S39.
41.
Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, Dinçer F, Dziedzic K, Häuselmann HJ, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Maheu E, Martín-Mola E, Pavelka K, Punzi L, Reiter S, Sautner J, Smolen J, Verbruggen G, Zimmermann-Górska I: Eular evidence based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2007;66:377-388.
42.
Liu Y, Yang H, Otaka K, Takatsuki H, Sakanishi A: Effects of vascular endothelial growth factor (VEGF) and chondroitin sulfate A on human monocytic THP-1 cell migration. Colloids Surf B Biointerfaces 2005;43:216-220.
43.
Foster RR, Armstrong L, Baker S, Wong DW, Wylie EC, Ramnath R, Jenkins R, Singh A, Steadman R, Welsh GI, Mathieson PW, Satchell SC: Glycosaminoglycan regulation by VEGFA and VEGFC of the glomerular microvascular endothelial cell glycocalyx in vitro. Am J Pathol 2013;183:604-616.
44.
Lambert C, Mathy-Hartert M, Dubuc JE, Montell E, Vergés J, Munaut C, Noël A, Henrotin Y: Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Res Ther 2012;14:R58.
45.
Zou J, Crews FT: Inflammasome-IL-1β signaling mediates ethanol inhibition of hippocampal neurogenesis. Front Neurosci 2012;6:77.
46.
Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE: Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol 2007;147:227-235.
47.
Schreiber S, Nikolaus S, Hampe J: Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998;42:477-484.
48.
Atreya I, Atreya R, Neurath MF: NF-kappaB in inflammatory bowel disease. J Intern Med 2008;263:591-596.
49.
Barnhill JG, Fye CL, Williams DW, Reda DJ, Harris CL, Clegg DO: Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial. J Am Pharm Assoc (2003) 2006;46:14-24.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.